{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:28:21Z","timestamp":1790875701835,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41591-026-04436-0","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:03:05Z","timestamp":1781082185000},"page":"2602-2609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dual-target gene therapy in Parkinson\u2019s disease: a multicenter phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9714-593X","authenticated-orcid":false,"given":"Mengyue","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-8719","authenticated-orcid":false,"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningdi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-3890","authenticated-orcid":false,"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4212-4231","authenticated-orcid":false,"given":"Dianyou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9797-9272","authenticated-orcid":false,"given":"Zhengyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuanyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengmin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4865-699X","authenticated-orcid":false,"given":"Yuanxin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-4806","authenticated-orcid":false,"given":"Xintian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-8578","authenticated-orcid":false,"given":"Lu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3653-2389","authenticated-orcid":false,"given":"Jiaji","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8300-8646","authenticated-orcid":false,"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"4436_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41583-024-00829-7","volume":"25","author":"J Gao","year":"2024","unstructured":"Gao, J. et al. Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nat. Rev. Neurosci. 25, 553\u2013572 (2024).","journal-title":"Nat. Rev. Neurosci."},{"key":"4436_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1474-4422(25)00125-5","volume":"24","author":"G Winston","year":"2025","unstructured":"Winston, G., Kharas, N., Svenningsson, P., Jha, A. & Kaplitt, M. G. Gene therapy for Parkinson\u2019s disease: trials and technical advances. Lancet Neurol. 24, 548\u2013556 (2025).","journal-title":"Lancet Neurol."},{"key":"4436_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks Jr","year":"2008","unstructured":"Marks, W. J. Jr et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol. 7, 400\u2013408 (2008).","journal-title":"Lancet Neurol."},{"key":"4436_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks, W. J. Jr et al. Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9, 1164\u20131172 (2010).","journal-title":"Lancet Neurol"},{"key":"4436_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"C Warren Olanow","year":"2015","unstructured":"Warren Olanow, C. et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78, 248\u2013257 (2015).","journal-title":"Ann. Neurol."},{"key":"4436_CR6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/mds.27724","volume":"34","author":"JD Heiss","year":"2019","unstructured":"Heiss, J. D. et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease. Mov. Disord. 34, 1073\u20131078 (2019).","journal-title":"Mov. Disord."},{"key":"4436_CR7","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","volume":"80","author":"RT Bartus","year":"2013","unstructured":"Bartus, R. T. et al. Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80, 1698\u20131701 (2013).","journal-title":"Neurology"},{"key":"4436_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/hum.2015.134","volume":"27","author":"WJ Marks Jr","year":"2016","unstructured":"Marks, W. J. Jr, Baumann, T. L. & Bartus, R. T. Long-term safety of patients with Parkinson\u2019s disease receiving rAAV2-neurturin (CERE-120) gene transfer. Hum. Gene Ther. 27, 522\u2013527 (2016).","journal-title":"Hum. Gene Ther."},{"key":"4436_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/mds.29426","volume":"38","author":"HJ Huttunen","year":"2023","unstructured":"Huttunen, H. J. et al. Intraputamenal cerebral dopamine neurotrophic factor in Parkinson\u2019s disease: a randomized, double-blind, multicenter phase 1 trial. Mov. Disord. 38, 1209\u20131222 (2023).","journal-title":"Mov. Disord."},{"key":"4436_CR10","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/mds.30193","volume":"40","author":"AD Van Laar","year":"2025","unstructured":"Van Laar, A. D. et al. Intraputaminal delivery of adeno-associated virus serotype 2-glial cell line-derived neurotrophic factor in mild or moderate Parkinson\u2019s disease. Mov. Disord. 40, 1297\u20131306 (2025).","journal-title":"Mov. Disord."},{"key":"4436_CR11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt, M. G. et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 369, 2097\u20132105 (2007).","journal-title":"Lancet"},{"key":"4436_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt, P. A. et al. AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309\u2013319 (2011).","journal-title":"Lancet Neurol."},{"key":"4436_CR13","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","volume":"2","author":"M Niethammer","year":"2017","unstructured":"Niethammer, M. et al. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease. JCI Insight 2, e90133 (2017).","journal-title":"JCI Insight"},{"key":"4436_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau0713","volume":"10","author":"M Niethammer","year":"2018","unstructured":"Niethammer, M. et al. Gene therapy reduces Parkinson\u2019s disease symptoms by reorganizing functional brain connectivity. Sci. Transl. Med. 10, eaau0713 (2018).","journal-title":"Sci. Transl. Med."},{"key":"4436_CR15","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine, C. W. et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662\u20131669 (2009).","journal-title":"Neurology"},{"key":"4436_CR16","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"JL Eberling","year":"2008","unstructured":"Eberling, J. L. et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980\u20131983 (2008).","journal-title":"Neurology"},{"key":"4436_CR17","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mt.2010.135","volume":"18","author":"S Muramatsu","year":"2010","unstructured":"Muramatsu, S. et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease. Mol. Ther. 18, 1731\u20131735 (2010).","journal-title":"Mol. Ther."},{"key":"4436_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine, C. W. et al. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann. Neurol. 85, 704\u2013714 (2019).","journal-title":"Ann. Neurol."},{"key":"4436_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/mds.27993","volume":"35","author":"JG Nutt","year":"2020","unstructured":"Nutt, J. G. et al. Aromatic L-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson\u2019s disease. Mov. Disord. 35, 851\u2013858 (2020).","journal-title":"Mov. Disord."},{"key":"4436_CR20","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","volume":"98","author":"CW Christine","year":"2022","unstructured":"Christine, C. W. et al. Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial. Neurology 98, e40\u2013e50 (2022).","journal-title":"Neurology"},{"key":"4436_CR21","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383, 1138\u20131146 (2014).","journal-title":"Lancet"},{"key":"4436_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/humc.2018.081","volume":"29","author":"S Palfi","year":"2018","unstructured":"Palfi, S. et al. Long-term follow-up of a phase i\/ii study of prosavin, a lentiviral vector gene therapy for Parkinson\u2019s disease. Hum. Gene Ther. Clin. Dev. 29, 148\u2013155 (2018).","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"4436_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone, M. C. & O\u2019Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529\u20131541 (2018).","journal-title":"Leukemia"},{"key":"4436_CR24","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","volume":"391","author":"CN Duncan","year":"2024","unstructured":"Duncan, C. N. et al. Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 391, 1287\u20131301 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4436_CR25","first-page":"2384","volume":"391","author":"DA Williams","year":"2024","unstructured":"Williams, D. A. Myelodysplasia after lentiviral gene therapy. Reply. N. Engl. J. Med. 391, 2384 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4436_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry, E. & Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839\u2013862 (2019).","journal-title":"Neuron"},{"key":"4436_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Current clinical applications of in vivo gene therapy with AAVs. Mol. Ther. 29, 464\u2013488 (2021).","journal-title":"Mol. Ther."},{"key":"4436_CR28","doi-asserted-by":"publisher","first-page":"101649","DOI":"10.1016\/j.gendis.2025.101649","volume":"13","author":"S Tang","year":"2025","unstructured":"Tang, S. et al. Hippocampus-targeted BDNF gene therapy to rescue cognitive impairments of Alzheimer\u2019s disease in multiple mouse models. Genes Dis. 13, 101649 (2025).","journal-title":"Genes Dis."},{"key":"4436_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/01.RES.88.2.137","volume":"88","author":"KA High","year":"2001","unstructured":"High, K. A. Gene transfer as an approach to treating hemophilia. Circ. Res. 88, 137\u2013144 (2001).","journal-title":"Circ. Res."},{"key":"4436_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/mthe.2000.0120","volume":"2","author":"JA Bristol","year":"2000","unstructured":"Bristol, J. A., Shirley, P., Idamakanti, N., Kaleko, M. & Connelly, S. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol. Ther. 2, 223\u2013232 (2000).","journal-title":"Mol. Ther."},{"key":"4436_CR31","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).","journal-title":"PLoS Biol."},{"key":"4436_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jneumeth.2015.05.008","volume":"251","author":"H Li","year":"2015","unstructured":"Li, H. et al. A quantitative approach to developing Parkinsonian monkeys (Macaca fascicularis) with intracerebroventricular 1-methyl-4-phenylpyridinium injections. J. Neurosci. Methods 251, 99\u2013107 (2015).","journal-title":"J. Neurosci. Methods"},{"key":"4436_CR33","doi-asserted-by":"publisher","first-page":"e0127953","DOI":"10.1371\/journal.pone.0127953","volume":"10","author":"X Lei","year":"2015","unstructured":"Lei, X. et al. 1-Methyl-4-phenylpyridinium stereotactic infusion completely and specifically ablated the nigrostriatal dopaminergic pathway in rhesus macaque. PLoS ONE 10, e0127953 (2015).","journal-title":"PLoS ONE"},{"key":"4436_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0306-4522(93)90176-G","volume":"52","author":"RD Smith","year":"1993","unstructured":"Smith, R. D., Zhang, Z., Kurlan, R., McDermott, M. & Gash, D. M. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52, 7\u201316 (1993).","journal-title":"Neuroscience"},{"key":"4436_CR35","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"4436_CR36","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1088\/0031-9155\/61\/22\/7975","volume":"61","author":"BA Thomas","year":"2016","unstructured":"Thomas, B. A. et al. PETPVC: a toolbox for performing partial volume correction techniques in positron emission tomography. Phys. Med. Biol. 61, 7975\u20137993 (2016).","journal-title":"Phys. Med. Biol."},{"key":"4436_CR37","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1007\/s00259-022-05752-6","volume":"49","author":"T Zhang","year":"2022","unstructured":"Zhang, T., Nie, B., Liu, H. & Shan, B. Unified spatial normalization method of brain PET images using adaptive probabilistic brain atlas. Eur. J. Nucl. Med. Mol. Imaging 49, 3073\u20133085 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04436-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04436-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04436-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:02:14Z","timestamp":1784210534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04436-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4436"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04436-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C., J.Z., W.J., Z.D., Y.Q. and X.X. are employees of Belief Biomed Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}